Kicking off #SIBCS2025 in Shanghai! Proud to represent Sage Publishing as Editor of Therapeutic Advances in Medical Oncology and Co-Editor of Clinical Medicine Insights: Oncology + Rare Tumors. Come say hi at booth #29! 🧬📚 #BreastCancer #Oncology #MedicalResearch

🔬 New insights into HER2-low TNBC: • 47.7% of Asian TNBC patients classified as HER2-low • Distinct genomic profile (↓ BRCA1, ↑ PIK3CA) • No difference in survival outcomes vs HER2-zero Full study 👉 buff.ly/kXKMwn8 #BreastCancer #HER2 #CancerResearch

Could the clock be a treatment factor? This retrospective study of 248 patients with mGC found better survival outcomes when nivolumab was infused before mid-afternoon. Authors suggest infusion timing should be considered in daily practice. Details here: buff.ly/k54we7o

🧬 Immunotherapy has transformed cancer care-but #prostatecancer remains resistant. This review explores why traditional approaches fall short and highlights emerging strategies like: Checkpoint inhibitors; T-cell engagers; CAR-T cells buff.ly/OV5DpZ2 #ProstateCancer #Immunotherapy #Oncology #CAR_T

🏠Can indoor radon affect lung cancer mutations? The RADON EUROPE study shows a link between high radon levels (>400 Bq/m³) and ALK rearrangements in NSCLC across 21 European countries.📍 This emphasizes the need for studying environmental impacts on cancer genomics. buff.ly/C3ktYC5 #LungCancer #NSCLC

📢 Study on advanced #PancreaticCancer treatment reveals key survival factors: Only 8.3% of 204 patients lived beyond 2 years. ✅ Longer survival linked to good physical function (PS 0), low CRP & CA 19-9, high albumin, and peritoneal metastasis without fluid buildup.

📢 Call for Papers! Submit to our special issue: “Geriatric Oncology: Advancing Cancer Care in an Aging World” buff.ly/ASkDwOt 🗓️ Join the conversation on cancer care for older adults. #GeriatricOncology #CancerResearch #Oncology #CallForPapers #MedicalPublishing

Adding anti-angiogenesis therapy to PD-1/PD-L1 + chemo improves PFS and ORR in ES-SCLC, especially in patients under 65. No OS benefit overall. Safety comparable. 🔗 buff.ly/tMshYDZ #LungCancer #CheckpointInhibitors #MetaAnalysis

PD-1/PD-L1 inhibitors show promise in HBV-related hepatocellular carcinoma. Patients with low HBV DNA and early qHBsAg response had longer survival. Viral biomarkers could shape future immunotherapy strategies. buff.ly/ciwROOE #LiverCancer #HBV #CheckpointInhibitors

Pregnancy after BC is not only possible - it’s often safe. But young survivors need tailored, multidisciplinary support to navigate fertility, treatment, and long-term health. More research is needed on novel agents like CDK4/6 and PARP inhibitors. buff.ly/l10yF3b #OncoFertility #BreastCancer

🧠 New real-world data on HER2-positive MIBC suggests limited benefit from adjuvant chemo or targeted therapy. With a 5-year DFS of 95.1%, this @tamedoncol.bsky.social study raises important questions about treatment necessity 🔗 buff.ly/HBeagpd #BreastCancer #HER2 #OncologyResearch

Precision matters. A new @tamedoncol.bsky.social review dives into the evolving landscape of non-clear cell RCC, emphasizing molecular profiling, novel targets, and the 2022 WHO reclassification. Read more: buff.ly/5jyCunC #RenalCellCarcinoma #nccRCC #TargetedTherapy

🚀 The future of #GastricCancer therapy may lie beyond traditional oncogenic targets. Explore how Claudin18.2, Nectin-4, and Caprin-1 are opening new doors for precision oncology in this @tamedoncol.bsky.social review. 🔗 journals.sagepub.com/doi/full/10.... #OncologyResearch #ESMO25 #CancerTherapy

🎉 Honoring excellence in oncology! Huge congratulations to our Associate Editor Dr. Natasha Leighl on receiving the #ESMO25 Women for Oncology Award. A true leader in advancing cancer care and inspiring the next generation of researchers. #WomenInSTEM #OncologyLeadership #lungcancer

In non-metastatic HER2− #BreastCancer, NCDB data (2018) showed higher pCR rates with neoadjuvant chemo in HR-Low vs HR-High groups. HR-Low tumors had higher grade/stage and lower endocrine therapy use, underscoring need for clearer treatment guidance. 🔗 journals.sagepub.com/doi/epdf/10....

In HR+ advanced #BreastCancer progressing after CDK4/6 inhibitors, network meta-analysis (19 RCTs; n=6621) found CDK4/6i + fulvestrant most effective for PFS, especially in visceral metastases or ESR1 mutations; Bcl-2i + Ful and SERDs also showed benefit journals.sagepub.com/doi/epdf/10....

In HER2+ salivary duct carcinoma, trastuzumab-deruxtecan (T-Dxd) achieved 13 months of disease control in a multitreated 44-year-old patient, supporting further study of anti-HER2 therapy in rare salivary tumors. 🔗 journals.sagepub.com/doi/epdf/10.... #HER2 #SalivaryCancer #Oncology

In HER2-mutated non-small-cell lung cancer, combination regimens achieved markedly better outcomes than single-agent approaches. Median PFS: 7.8 vs 5.3 mo; best results seen with chemo + immunotherapy + anti-angiogenic therapy. 🔗 journals.sagepub.com/doi/epdf/10....

In patients with metastatic #gastriccancer, earlier nivolumab monotherapy infusions (before 14:00) were associated with significantly longer PFS and OS (7.6 vs 3.9 mo). Authors suggest infusion timing may influence outcomes in #Immunotherapy practice. 🔗 journals.sagepub.com/doi/epdf/10....

🚨 Call for Papers – Special Collection! @tamedoncol.bsky.social seeks submissions on: De-escalation of Treatment in Gynecologic Cancers. 🗓️ Submit by March 18, 2026 📥 Submit:

Ontario study of OHIP data (2015–2022): female cancer diagnostic billing dropped in 2020 (cervical −50.7/100k, breast −13.9/100k) but rebounded sharply in 2021–22, with net excesses across all cancer types. COVID-19 disruptions drove delayed diagnoses. journals.sagepub.com/doi/epdf/10....

Phase III FLINTER trial (N=317) shows rituximab biosimilar DRL_RI is equivalent to MabThera® in untreated low–tumor-burden follicular lymphoma: BORR 80.2% vs 79.4% (Δ0.9%, CI within ±17%). Safety, immunogenicity, PK/PD profiles comparable. #Lymphoma journals.sagepub.com/doi/epdf/10....

Study of 2896 early-stage #BreastCancer pts: CanAssist Breast prognostic test stratified ER1–20% subgroup. 65% classified low risk with 91% DRFI, 35% high risk with 61% DRFI. CAB may guide tailored therapy beyond ER levels in this challenging group. journals.sagepub.com/doi/epdf/10....

Propensity-matched study (n=127) in extensive-stage #SCLC after first-line chemoimmunotherapy: prophylactic cranial irradiation (PCI) did not improve OS overall but reduced brain metastases (1-yr 13.8% vs 53.4%). OS benefit seen in partial responders. journals.sagepub.com/doi/epdf/10....

Systematic review & network meta-analysis in advanced EGFR-mutated #NSCLC after TKI failure: chemo+ivonescimab ranked best for PFS with acceptable safety; chemo+amivantamab gave strongest OS/ORR but higher toxicity. Chemo+IO or chemo alone less effective. journals.sagepub.com/doi/epdf/10....

Phase IV CoVigi trial: in 204 pts with solid #cancer on therapy, 92% developed anti-S antibodies after 2nd BNT162b2 dose; all seroconverted by 6 mo. Chemotherapy impaired both humoral & cellular responses, while prior COVID-19 infection boosted immunity. journals.sagepub.com/doi/epdf/10....

Multicenter Mexican cohort (n=477) of young women with #BreastCancer (≤40 yrs): 62% followed a poor long-term QoL trajectory over 5 yrs, with declines in sexual health & future perspective. HER2+ status & public insurance linked to better QoL outcomes. journals.sagepub.com/doi/epdf/10....

Retrospective study of 110 high-risk rectal cancer pts: total neoadjuvant therapy achieved organ preservation in ~50% with 3-yr DFS 75.7% OS 92.4%. Watch & wait strategy gave superior outcomes vs non-pCR pts. TNT supports durable survival & bowel function journals.sagepub.com/doi/epdf/10....

Study in advanced #GastricCancer: flow cytometry of peritoneal lavage showed CD44+/CD326+ tumor cells correlate with response to repeated intraperitoneal perfusion chemotherapy (RIPPENC). Lower levels linked to resection eligibility & longer survival. journals.sagepub.com/doi/epdf/10....

Phase Ib study of xevinapant + avelumab in advanced solid tumours & #NSCLC: RP2D established at 200 mg/day, safety manageable. In NSCLC (n=38), ORR 10.5% (not superior to avelumab alone). Biomarker analyses highlight immune signatures tied to response journals.sagepub.com/doi/epdf/10....

Systematic review & meta-analysis (9 RCTs) in advanced gastric cancer: #immunotherapy + chemo did not improve OS/PFS vs chemo alone in pts with low PD-L1 (CPS<1 or <5). Dual antibody regimens showed PFS benefit (HR 0.64), warranting further study. Read: journals.sagepub.com/doi/epdf/10....

Retrospective study of 213 late-stage cancer pts in Jordan evaluates #NGS. Clinically significant alterations in 42% (KRAS, PIK3CA, ERBB2, EGFR, BRCA). PFS markedly improved with NGS-guided therapy (HR 0.216) though cost & drug access remain major barriers journals.sagepub.com/doi/epdf/10....

#TopReadTuesday from TAM: Aberrant DNA methylation is a hallmark of cancer, driving initiation, progression & therapy resistance. This review details clinical impacts from MMR gene silencing to BRCA1 methylation loss under treatment pressure. 🔗 journals.sagepub.com/doi/epdf/10....

In NSCLC patients with bone metastases, those receiving palliative RT during ICI treatment had significantly better survival: median OS 16 mo vs 3 mo; PFS also improved. These findings support a synergistic role for RT with immunotherapy. 🔗 journals.sagepub.com/doi/epdf/10....

In real-world data from 147 advanced BTC patients refractory to gem/cis, second-line 5-FU-based therapy showed modest survival (median OS 4.8 mo). FOLFOX had comparable efficacy but better safety than Nal-IRI/FL or FOLFIRINOX—supporting role as 2L option. journals.sagepub.com/doi/epdf/10....

New real-world data from China compares flumatinib vs nilotinib as 1L treatment for chronic phase CML (n=165): 🔹 Similar MMR at 12 mo (85.1% vs 88.2%) 🔹 Nilotinib led to higher MR4 at all timepoints 🔹 Flumatinib had fewer metabolic/liver AEs 🔗 journals.sagepub.com/doi/epdf/10....

In mRCC, second-line ICI vs TKI showed similar OS (44.8 vs 41.1 mo; p=0.446). But in NLR-high patients, TKI→ICI led to better survival vs TKI→TKI. Bone mets and nephrectomy history also influenced outcomes. 👉 NLR may guide 2L therapy: doi.org/10.1177/1758...

In a cohort of 514 cancers, high ICOS expression (14%) was linked to elevated PD-1, PD-L1 & CTLA-4 RNA (all p<0.05) but not survival in ICI-treated or immunotherapy-naïve patients. Suggests ICOS ≠ prognostic, but may guide combo ICI strategies. doi.org/10.1177/1758...

📌 In a Chinese LCNEC cohort (n=151), median OS was 17.8 mo. Adjuvant chemo post-surgery reduced distant spread & improved 2-yr OS (37.1% vs 79.9%, p<0.001). Immunochemotherapy outperformed chemo alone in advanced disease. doi.org/10.1177/1758...

📊 In non-resectable stage III melanoma, T-VEC and IL-2 showed no significant differences in PFS (5.0 mo), OS (34.0 mo), or response rates. Both were well tolerated with minimal AEs. Real-world data to guide intralesional therapy choice. doi.org/10.1177/1758...

3 patients with metastatic KRAS-wildtype PDAC showed prolonged response to osimertinib after EGFR exon 19 deletion was found via NGS. Early molecular & metabolic responses seen; disease controlled for 6, 8, and 17 months. A case for rare mutation testing journals.sagepub.com/doi/epdf/10....

First reported case of coma from luminal breast cancer brain mets reversed without radiation: patient treated w/ nasogastric abemaciclib + fulvestrant post-surgery. Seizures resolved, imaging improved, full functional recovery—patient returned to work journals.sagepub.com/doi/epdf/10....

Checkpoint inhibitors are now standard in advanced HCC, but resistance is common. This review explores how TACE, radiation, and novel combos (triplets, bispecifics, vaccines) may expand efficacy and indications. Read here: journals.sagepub.com/doi/epdf/10....

🧵April is National Cancer Control Month. We're highlighting research that reflects commitment to improving cancer care—through innovative therapies, cost-effectiveness, and global equity. Here are some articles from the past year ⬇️

🔍 A new review explores the toxicity profiles and management strategies of emerging antibody–drug conjugates (ADCs) in breast cancer. From ILD to neutropenia, understanding these effects is key to maximizing benefit across all BC subtypes Read here: journals.sagepub.com/doi/epdf/10....

(1/6) Freedom of expression and inquiry are integral to education and we work to uphold these principles in everything we publish. Learn how we're amplifying voices impacted by censorship and strengthening academic freedom 👇 Read the report: bit.ly/iwi24

🩻Breast imaging in Thai transgender women aged 40+ (avg 16 yrs HRT) showed high breast density and low abnormality rates. Most (80%) had augmentation; 94% of findings were benign or negative. Supports need for dual-modality screening. Read here: journals.sagepub.com/doi/epdf/10....

📘 A practical guide on adjuvant CDK4/6 inhibitors for HR+, HER2− early breast cancer, integrating real-world insights on abemaciclib vs ribociclib, toxicity management, and care delivery—rooted in monarchE and NATALEE findings. 🔗 journals.sagepub.com/doi/epdf/10....

🩺 After TACE conversion therapy for unresectable HCC, surgical resection (SR) offered better OS and DFS than microwave ablation (MWA) (OS: 10.6 vs 5.8 yrs; HR: 1.83; p < 0.001). But in patients <45 or meeting Milan criteria, outcomes were comparable. 🔗 journals.sagepub.com/doi/epdf/10....

🧬 Extensive-stage small-cell lung cancer: Immune checkpoint inhibitors like atezolizumab & durvalumab have improved survival when added to chemotherapy. New strategies—lurbinectedin, anti-DLL3 antibodies & subtype-based approaches—are in development 🔗 journals.sagepub.com/doi/epdf/10....